DeepMed Research

Arsenic trioxide

Generic Name: Arsenic trioxide

Brand Names: Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac

Drug Type: Small Molecule

Chemical Formula: As_₂O_₃

CAS Number: 1327-53-3

Unique Ingredient Identifier: S7V92P67HO

Background: Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

Indication: For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Associated Conditions: Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia

Clinical Trials

Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Terminated

Conditions: Adenocarcinoma of the Esophagus
Stage III Esophageal Cancer
Stage IV Esophageal Cancer

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-06-06

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00061958

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-05-21

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005999

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-01-28

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 13

Registration Number: NCT00053222

Locations: 🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States

and more 8 locations

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-28

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00053248

Locations: 🇺🇸
UCLA Department of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020111

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

and more 49 locations

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-05

Lead Sponsor: CTI BioPharma

Registration Number: NCT00020969

Locations: 🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Lynn Regional Cancer Center West, Boca Raton, Florida, United States

and more 5 locations

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-05

Lead Sponsor: CTI BioPharma

Registration Number: NCT00017069

Locations: 🇺🇸
Mountain States Tumor Institute - Boise, Meridian, Idaho, United States
🇺🇸
Texas Cancer Care, Fort Worth, Texas, United States
🇺🇸
Rocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States

and more 7 locations

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Not Applicable

Terminated

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Prolymphocytic Leukemia
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Splenic Marginal Zone Lymphoma

Interventions: Drug: arsenic trioxide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00005786

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 35

Registration Number: NCT00016159

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Arsenic Trioxide in Treating Men With Germ Cell Cancer

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00036842

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 91 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy